Resveratrol

Pricing Availability   Qty
Cat.No. 1418 - Resveratrol | C14H12O3 | CAS No. 501-36-0
Description: Cyclooxygenase inhibitor
Chemical Name: 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol
Purity: ≥98% (HPLC)
Datasheet
Citations (7)
Reviews
Literature

Biological Activity

A phytoestrogen with antitumor, antioxidant, antiplatelet, anti-inflammatory and antifungal effects. Inhibits cytochrome P450 1A1 (IC50 = 23 μM) and displays mixed agonist/antagonist actions at ERα and ERβ estrogen receptors. Converted into the anticancer agent piceatannol (Cat. No. 1554) by cytochrome P450 1B1. Activates autophagy. Also activates TRPA1 in prostate cancer-associated fibroblasts. Also SIRT1 activator.

Compound Libraries

Resveratrol is also offered as part of the Tocriscreen Plus and Tocriscreen Epigenetics Toolbox. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 228.25
Formula C14H12O3
Storage Desiccate at +4°C
Purity ≥98% (HPLC)
CAS Number 501-36-0
PubChem ID 445154
InChI Key LUKBXSAWLPMMSZ-OWOJBTEDSA-N
Smiles OC1=CC=C(C=C1)\C=C\C1=CC(O)=CC(O)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solubility Soluble to 100 mM in ethanol and to 100 mM in DMSO

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Baur and Sinclair (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat.Rev.Drug Discov. 5 493 PMID: 16732220

Bowers et al (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinology 141 3657 PMID: 11014220

Chun et al (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem.Biophys.Res.Commun. 262 20 PMID: 10448061

Fremont (2000) Biological effects of resveratrol. Life Sci. 66 663 PMID: 10680575

Kimura et al (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim.Biophys.Acta 834 275 PMID: 3922423

Baptista et al (2013) Regulation of histone H2A.Z exprsesion is mediated by sirtuin 1 in prostate cancer. Oncotarget 4 1673 PMID: 24127549

Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316

Vancauwenberghe et al (2017) Activation of mutated TRPA1 ion channel by resveratrol in human prostate cancer associated fibroblasts (CAF). Mol.Carcinog. 56 1851 PMID: 28277613


If you know of a relevant reference for Resveratrol, please let us know.

View Related Products by Product Action

View all Cyclooxygenase Inhibitors

Keywords: Resveratrol, Resveratrol supplier, Antitumor, anti-oxidant, agent, Cyclooxygenase, inhibitors, inhibits, COX, Oxygenases, Oxidases, Antiangiogenics, Antioxidants, Class, III, HDACs, (Sirtuins), Autophagy, TRPA1, 1418, Tocris Bioscience

7 Citations for Resveratrol

Citations are publications that use Tocris products. Selected citations for Resveratrol include:

Chen et al (2014) A critical role for IF. regulatory factor 9 in cerebral ischemic stroke. J Neurosci 34 11897 PMID: 25186738

Rojas et al (2014) Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci 8 24 PMID: 24570655

Jiang and Zsombok (2014) Regulation of neurons in the dorsal motor nucleus of the vagus by SIRT1. Front Neurosci 7 270 PMID: 24454277

Wang et al (2013) Active Constituents from Liriope platyphylla Root against Cancer Growth In Vitro. Cancer Res 2013 857929 PMID: 23762164

Ohshiro et al (2007) Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Br J Pharmacol 67 8164 PMID: 17804729

Meftahi et al (2015) Suppressive Effects of Resveratrol Treatment on The Intrinsic Evoked Excitability of CA1 Pyramidal Neurons. Evid Based Complement Alternat Med 17 532 PMID: 26464825

Pacholec et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285 8340 PMID: 20061378


Do you know of a great paper that uses Resveratrol from Tocris? Please let us know.

Reviews for Resveratrol

There are currently no reviews for this product. Be the first to review Resveratrol and earn rewards!

Have you used Resveratrol?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Immunology

Immunology Product Listing

A collection of over 190 products for immunology research, the guide includes research tools for the study of:

  • Chemokine and Cytokine Signaling
  • Chemotaxis
  • Complement System
  • Immune Cell Signaling
  • Inflammation
Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Asthma

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.